Brief: ADC Therapeutics Announces Updated Lotis-2 Results
June 9 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS ANNOUNCES UPDATED LOTIS-2 RESULTS
DEMONSTRATING
DURABLE, LONG-TERM RESPONSES OF ZYNLONTA® IN RELAPSED/REFRACTORY
DLBCL
* ADC THERAPEUTICS SA - NO NEW SAFETY SIGNALS WERE
IDENTIFIED
Source text for Eikon: ID:nGNXccw6pM
Further company coverage: ADCT.N
(reuters.briefs@thomsonreuters.com)
Recent news on ADC Therapeutics SA
See all newsADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million